Search results
Showing 1096 to 1110 of 7707 results
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) (TA647)
NICE is unable to make a recommendation on eculizumab (Soliris) for treating relapsing neuromyelitis optica because Alexion Pharma UK did not provide an evidence submission.
Show all sections
Sections for TA647
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.
View recommendations for TA179Show all sections
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.
View recommendations for TA184Show all sections
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
NICE is unable to make a recommendation about the use in the NHS of enzalutamide (Xtandi) for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because Astellas Pharma did not provide an evidence submission.
Show all sections
Sections for TA994
Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)
Evidence-based recommendations on paclitaxel for treating ovarian cancer in adults.
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)
Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer in adults.
View recommendations for TA100Show all sections
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.
HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) (TA92)
Evidence-based recommendations on using an ozone-releasing device (HealOzone) in people with tooth decay.